Felix Theeuwes

FELIX THEEUWES is Chairman, co-Founder, and Chief Scientific Officer at
DURECT Corporation, established in July 1998 as a spinout from ALZA
Corporation to focus on the development of pharmaceutical systems and
products to treat chronic debilitating diseases and enabling
biotechnology drugs. Dr. Theeuwes was with ALZA Corporation from 1970
until June 1999, holding positions directing research, technology
development and product development for a variety of controlled drug
delivery systems. His work led to the product introduction of the ALZET’
mini osmotic pump series for animal research, and the OROS’ systems
series of products. He directed research in transdermal research and
development, initiated the electrotransport/iontophoresis program, and
initiated the DUROS’ osmotic implant program. He holds more than 210 US
patents covering these systems and published more than 80 articles and
book chapters. In 1980 Dr. Theeuwes was named Inventor of the Year by
the Peninsula Patent Law Association. In 1983 he was the recipient of
the Award for the Advancement of Industrial Pharmacy. He was the Busse
Lecturer at the University of Wisconsin in 1981, and in 1985 the Third
Annual Sidney Riegelman Lecturer at the University of California, San
Francisco. He is a Fellow of the American Association of Pharmaceutical
Scientists. In 1993 he became the first recipient of ALZA Corporation’s
Founder’s Award. Dr. Theeuwes is a member of the Board of Directors at
Genetronics, Inc., and DURECT Corporation and was formerly a member of
the Scientific Advisory Board at Antigenics. In 1993 Dr. Theeuwes
completed the Stanford Executive Program. He received his undergraduate
and graduate education in Physics at the University of Leuven (Louvain),
Belgium, with a DSc degree in 1966. From 1966 to 1970 he served as a
post-doctoral fellow and visiting Research Assistant Professor in the
Department of Chemistry, University of Kansas.